MétaCan
Menu
Back to cohort
Record W2610105836 · doi:10.1093/neuonc/nox036.006

OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas

2017· article· en· W2610105836 on OpenAlexaff
Erica H. Bell, P. Zhang, Kenneth Aldape, J. McElroy, Minesh P. Mehta, Jessica L. Fleming, Z. Liu, Stephen W. Coons, Derek R. Johnson, Arnab Chakravarti

Bibliographic record

VenueNeuro-Oncology · 2017
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsOncologyInternal medicineMedicineHazard ratioGliomaProgression-free survivalMethylationProportional hazards modelOligodendrogliomaO-6-methylguanine-DNA methyltransferaseBiomarkerStatistical significanceMethyltransferaseAstrocytomaOverall survivalConfidence intervalBiologyCancer researchGeneGenetics

Abstract

fetched live from OpenAlex

Background: This study sought to determine the proportion of patients with MGMT promoter methylation within NRG Oncology/RTOG 9802 and its prognostic significance in the setting of high-risk low-grade gliomas in a prospective phase III trial. Methods: NRG Oncology/RTOG 9802 enrolled 251 eligible high-risk patients, treated with RT or RT + PCV. The MGMT-STP27 prediction model was used to calculate MGMT promoter methylation status from Illumina HM-450K data. Univariate (UMAs) and multivariate analyses (MVAs) were performed using the Cox proportional hazard model, to analyze the effect of MGMT status on progression-free survival (PFS) and overall survival (OS). Patient pre-treatment characteristics and treatment assignment were included as covariates in MVAs. Results: Of all the eligible and randomized patients in this trial, 56 currently have MGMT status available: 43 (77%) methylated and 13 (23%) unmethylated. Between the two groups, no significant difference was observed on age and performance status at baseline. Majority of the unmethylated patients had astrocytoma dominant tumors as opposed to oligodendroglioma in the methylated group. Upon UVAs, MGMT promoter methylation was significantly correlated with better OS (HR = 2.66; p=0.01) and PFS (HR = 2.52; p=0.01). Upon MVAs, the statistical significance was maintained for PFS (HR = 3.57; p=0.001), but not OS (HR = 1.68; p=0.25). Conclusions:MGMT promoter methylation as determined by the MGMT- STP27 model was an independent prognostic biomarker of high-risk low-grade glioma treated with radiation or radiation plus PCV for PFS. Importantly, this is the first study to validate the prognostic significance of MGMT promoter methylation in a phase III study of high-risk grade II glioma patients treated with radiation plus/minus PCV using rigorous MVAs with prospectively-collected, well-annotated clinical data. Analysis of the prognostic significance of MGMT promoter methylation relative to IDH and 1p/19q status is ongoing as well as efforts to increase sample size. FUNDING: U10CA180868, U10CA180822, and U24CA196067 (NCI). Also, R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01 (NCI), Brain Tumor Funders Collaborative Grant, and the Ohio State University CCC (all to AC).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.471
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.359
Teacher spread0.327 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicGlioma Diagnosis and TreatmentFrench-language works237,207